4D Molecular Therapeutics, Inc. recorded an outflow of $109.6M in free cash flow in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters 4D Molecular Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
FDMT Free Cash Flow by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
FDMT Free Cash Flow by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More 4D Molecular Therapeutics, Inc. financials
Frequently Asked Questions
4D Molecular Therapeutics, Inc. recorded an outflow of $109.6M in free cash flow in fiscal year 2025.
4D Molecular Therapeutics, Inc. (FDMT) reported an outflow of $138.4M in free cash flow in fiscal year 2024 and an outflow of $109.6M in free cash flow in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 7 fiscal years this page covers, 4D Molecular Therapeutics, Inc. (FDMT) free cash flow went from -$39.9M in fiscal year 2019 to -$109.6M in fiscal year 2025.
4D Molecular Therapeutics, Inc. (FDMT) reported -$56.8M in free cash flow in Q3 2026.
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what 4D Molecular Therapeutics, Inc. (FDMT) reported on that line in every period on record.